

<英文原著>

1. **Sugimoto M**, Chujo S, Kato K, Shimura M, Kitano S, Kusuhara S, Terasaki H, Kondo M, Writing Committee Of Japan-Clinical Retina Study Group J-Crest. Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents. *J Clin Med*. 2024; 13:7336.
2. Yoshimura A, Ishikawa H, Uchida K, Takesue Y, Mori J, Kinoshita T, Morikawa S, Okamoto F, Sawada T, Ohji M, Kanda T, Takeuchi M, Miki A, Kusuhara S, Ueda T, Ogata N, **Sugimoto M**, Kondo M, Yoshida S, Ogata T, Kimura K, Mitamura Y, Jujo T, Takagi H, Terasaki H, Sakamoto T, Sugisawa T, Komuku-Yamamoto Y, Gomi F. Risk Factors for Legal Blindness in 237 Japanese Patients with Exogenous Endophthalmitis: A Multicenter Cohort Study from J-CREST. *Ocul Immunol Inflamm*. 2024; 32:1133-1141.
3. Kashima Y, Kato K, Chujo S, Nagashima R, Co, Matsubara H, Matsui Y, Tenma Y, **Sugimoto M**, Kondo M. Transient increase of flicker electroretinograms after combined cataract surgery and vitrectomy for idiopathic epiretinal membrane. *Sci Rep*. 2024; 14:23634.
4. Hirano T, Murata T, Nakao S, Shimura M, Nozaki M, Suzuma K, Nagaoka T, **Sugimoto M**, Takamura Y, Murakami T, Iwasaki K, Tsujimura J, Yoshida S. Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial. *PLoS One*. 2024; 19:e0311484.
5. Namba H, Maeda N, Tsukamoto M, **Utsunomiya H**, **Kaneko Y**, Nishitsuka K, **Yamashita H**, Ohta Y, Usui T, **Sugimoto M**. Associations of ocular anterior segment structures with sex and age: the Yamagata study (Funagata). *Jpn J Ophthalmol*. 2024; 68:751-763.
6. Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators (**Sugimoto M**). Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. *Ophthalmology*. 2024; 131: 708-723.
7. Chujo S, Matsubara H, Ichio A, Matsui Y, **Sugimoto M**, Kondo M. Three cases of acute retinal necrosis with atypical fundus FINDINGS. *Retinal Cases & Brief Reports* 2024; 18: 308-311.

8. Nakagawa-Saito Y, Mitobe Y, **Togashi K**, Suzuki S, Sugai A, Takenouchi S, Nakamura K, Sonoda Y, Kitanaka C, Okada M. The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. *Int J Mol Sci.* 2024; 25:3948.
9. Mitobe Y, Suzuki S, Nakamura K, Nakagawa-Saito Y, Takenouchi S, **Togashi K**, Sugai A, Sonoda Y, Kitanaka C, Okada M. CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignant Brain Tumor Cells. *Int J Mol Sci.* 2024; 25:9473.
10. Mitobe Y, Suzuki S, Nakagawa-Saito Y, **Togashi K**, Sugai A, Sonoda Y, Kitanaka C, Okada M. Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells. *Cancers (Basel).* 2023;15:4326.
11. Nakamura K, Ito Y, Takenouchi S, Nakagawa-Saito Y, Suzuki S, **Togashi K**, Sugai A, Mitobe Y, Sonoda Y, Kitanaka C, Okada M. Effective Targeting of Glioma Stem Cells by BSJ-04-122, a Novel Covalent MKK4/7 Dual Inhibitor. *Anticancer Res.* 2025; 45:2917-2924.
12. Takenouchi S, Ito Y, Nakamura K, Nakagawa-Saito Y, Mitobe Y, **Togashi K**, Suzuki S, Sugai A, Sonoda Y, Kitanaka C, Okada M. Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells. *Int J Mol Sci.* 2025; 26:6984.
13. Nakagawa-Saito Y, Mitobe Y, **Togashi K**, Suzuki S, Sugai A, Takenouchi S, Nakamura K, Sonoda Y, Kitanaka C, Okada M. The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. *Int J Mol Sci.* 2024; 25:3948.
14. Fukuyama H, Ishikawa H, Gomi F; Japan-Retinal Detachment Registry Group. Impact of drainage retinotomy on surgical outcomes of retinal detachment: insights from the Japan-Retinal Detachment Registry (**Sugimoto M**, **Kaneko Y**, **Nishi K**). *Sci Rep.* 2024; 14:7795.

<総説・解説記事>

1. **杵本 昌彦**. アイバンク理事長挨拶. 山形県アイバンク機関誌.
2. **杵本 昌彦**. 黄斑浮腫と類似所見を見極める! 「DME」. Retina Medicine.
3. **杵本 昌彦**. 抗 VEGF 治療セミナー「糖尿病網膜症治療:実臨床と私のこだわり」. あたらしい眼科.

<著書>

1. **杵本 昌彦**. 眼科診療ガイド第2版. 17. 全身疾患と眼疾患 2)母斑症 ③結節性硬化症. 文光堂. 657-658. 20241102
2. **金子優**. 眼科診療ガイド第2版. 17. 全身疾患と眼疾患 9)皮膚疾患 ④川崎病. 723-724. 20241100.
3. **金子優**. 眼科診療ガイド第2版. 17. 全身疾患と眼疾患. 9)皮膚疾患. ③Rothmund-Thomson 症候群. 722-723. 20241100

<海外講演>

一般口演

1. **Sugimoto M**. Effect of pregnancy on progression of diabetic retinopathy. 2024/03/22. Fuji Retina (Tokyo).

ポスター

1. **Sugimoto M**, Kondo M, D'Alessandro-Gabazza CN, Toda M, Yasuma T, Gabazza EC. Protein S behavior for pregnancy associated with impaired glucose tolerance. 2024/05/05. ARVO(Seattle)
2. **Togashi K**, Suzuki S, Mitobe Y, Nakagawa-Saito Y, Sugai A, Takenouchi S, **Sugimoto M**, Kitanaka C, Okada M. Novel Molecularly Targeted Therapy for Retinoblastoma Through Activation of MDM4-p53 Pathway. 2024/05/05. ARVO(Seattle)
3. **Iwasaki H**. A case of steroid-resistant optic neuritis treated with a single plasma exchange therapy. 2024/03/22. Fuji Retina (Tokyo).
4. **Sato H**. A case of blurred vision leading to the diagnosis of infective endocarditis. 2024/03/22. Fuji Retina (Tokyo).